{
    "eid": "2-s2.0-85146038650",
    "title": "Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis",
    "cover-date": "2023-03-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Immunology and Allergy",
            "@code": "2723",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Immunology",
            "@code": "2403",
            "@abbrev": "IMMU"
        }
    ],
    "keywords": [
        "Asthma",
        "Bayesian",
        "benralizumab",
        "comparative effectiveness",
        "dupilumab",
        "eosinophilic",
        "mAb",
        "mepolizumab",
        "network meta-analysis",
        "tezepelumab"
    ],
    "authors": [
        "Tanawin Nopsopon",
        "Grace Lassiter",
        "Ming Li Chen",
        "G. Caleb Alexander",
        "Corinne Keet",
        "Hwanhee Hong",
        "Ayobami Akenroye"
    ],
    "citedby-count": 4,
    "ref-count": 48,
    "ref-list": [
        "Asthma severity and medical resource utilisation",
        "Extent, patterns, and burden of uncontrolled disease in severe or difficult-to-treat asthma",
        "Systematic literature review of the clinical, humanistic, and economic burden associated with asthma uncontrolled by GINA steps 4 or 5 treatment",
        "US Food and Drug Administration. Novel drug approvals for 2015",
        "Novel drug approvals for 2017",
        "New drug therapy approvals 2019",
        "FDA approves maintenance treatment for severe asthma",
        "Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: a Bayesian network meta-analysis",
        "Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors for the treatment of severe asthma: a systematic review",
        "Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: indirect treatment comparison",
        "Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison",
        "The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations",
        "Automating network meta-analysis",
        "Evaluation of networks of randomized trials",
        "Measurement properties and interpretation of three shortened versions of the asthma control questionnaire",
        "Minimal clinically important difference for asthma endpoints: an expert consensus report",
        "Tezepelumab in adults with uncontrolled asthma",
        "Baseline type 2 biomarker levels and response to tezepelumab in severe asthma",
        "Tezepelumab in adults and adolescents with severe, uncontrolled asthma",
        "Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial",
        "The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM)",
        "Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study",
        "Mepolizumab treatment in patients with severe eosinophilic asthma",
        "Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial",
        "Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial",
        "Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial",
        "Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial",
        "Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial",
        "Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma",
        "Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial",
        "Anti-TSLP antibodies: targeting a master regulator of type 2 immune responses",
        "Induction of IL-4 expression in CD4(+) T cells by thymic stromal lymphopoietin",
        "TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand",
        "The group 2 innate lymphoid cell (ILC2) regulatory network and its underlying mechanisms",
        "Targeting key proximal drivers of type 2 inflammation in disease",
        "Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma",
        "The cytokine network in asthma and chronic obstructive pulmonary disease",
        "Molecular targets for biological therapies of severe asthma",
        "Sub-stratification of type-2 high airway disease for therapeutic decision-making: a \u201cbomb\u201d (blood eosinophils) meets \u201cmagnet\u201d (FeNO) framework",
        "Prognostic and predictive value of blood eosinophil count, fractional exhaled nitric oxide, and their combination in severe asthma: a post hoc analysis",
        "Effect of anti-IL5, anti-IL5R, anti-IL13 therapy on asthma exacerbations: a network meta-analysis",
        "Dupilumab efficacy in patients stratified by baseline treatment intensity and lung function",
        "Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction",
        "The interleukin-13 paradox in asthma: effective biology, ineffective biologicals",
        "Anti-IL5 therapies for asthma",
        "Association between pulmonary function and asthma symptoms",
        "Validation of the Spanish version of the Asthma Control Questionnaire",
        "Asthma characteristics and biomarkers from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) longitudinal profiling study"
    ],
    "affiliation": [
        {
            "affiliation-city": "Boston",
            "@id": "60016782",
            "affilname": "Brigham and Women's Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016782",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Baltimore",
            "@id": "60006183",
            "affilname": "Johns Hopkins Bloomberg School of Public Health",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60006183",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Boston",
            "@id": "60032499",
            "affilname": "Harvard T.H. Chan School of Public Health",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60032499",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Taichung",
            "@id": "60027767",
            "affilname": "Chung Shan Medical University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60027767",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Chapel Hill",
            "@id": "60025111",
            "affilname": "The University of North Carolina at Chapel Hill",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60025111",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "New York",
            "@id": "60019868",
            "affilname": "Weill Cornell Medical Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60019868",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Durham",
            "@id": "60005200",
            "affilname": "Duke University School of Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60005200",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Baltimore",
            "@id": "115943994",
            "affilname": "Center for Drug Safety and Effectiveness",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/115943994",
            "affiliation-country": "United States"
        }
    ],
    "funding": [
        "National Institutes of Health",
        "National Institutes on Minority Health and Health Disparities"
    ]
}